CART30

CART30 is a CD30-directed Chimeric Antigen Receptor T-cell (CAR-T) therapy. It is designed to treat CD30-positive lymphomas, including Hodgkin's lymphoma and Non-Hodgkin's lymphoma, by targeting the CD30 antigen on tumor cells. A specific academic product, HSP-CAR30, is a modified version of CART30 that targets a proximal epitope within the nonsoluble part of CD30 and is manufactured with the addition of interleukin-21 (IL-21) to IL-7 and IL-15 to promote the stemness of T cells, aiming to improve efficacy and durable responses.

Other names

Anti-CD30 chimeric antigen receptor T-cell therapyAnti-CD-30 chimeric antigen receptor T-cell therapyAnti-CD 30 chimeric antigen receptor T-cell therapyanti CD30 CAR T细胞CD30-directed chimeric antigen receptor T-cell therapyCD-30-directed chimeric antigen receptor T-cell therapyCD 30-directed chimeric antigen receptor T-cell therapyCAR30 T-cellCAR-30 T-cellCAR 30 T-cell